Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Bristol-Myers Squibb
Bristol-Myers Squibb
M.D. Anderson Cancer Center
BioNTech SE
Kaiser Permanente
Medicine Invention Design, Inc
National Cancer Institute (NCI)
Pfizer
Bristol-Myers Squibb
Swiss Cancer Institute
Mirati Therapeutics Inc.
Canadian Cancer Trials Group
AbbVie
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai Henlius Biotech
Hoffmann-La Roche
NRG Oncology
Cancer Research UK
AbbVie
SWOG Cancer Research Network
Hoffmann-La Roche
Second Affiliated Hospital of Nanchang University
TJ Biopharma Co., Ltd.
Eikon Therapeutics
SWOG Cancer Research Network
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals